Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature.
Farrar
H C
HC
Division of Pediatric Pharmacology, Case Western Reserve School of Medicine, Cleveland, OH.
Walsh-Sukys
M C
MC
Kyllonen
K
K
Blumer
J L
JL
D001919:Bradycardia / Q000139:chemically induced*; D004917:Erythromycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006323:Heart Arrest / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000139:chemically induced* / Q000188:drug therapy; D007262:Infusions, Intravenous; D008297:Male; D016869:Ureaplasma Infections / Q000188:drug therapy; D016990:Ureaplasma urealyticum
C010948:erythromycin lactobionate; D004917:Erythromycin